Punit Yadav
University of Birmingham
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Punit Yadav.
PLOS ONE | 2014
Khai Ping Ng; Stephanie Stringer; Mark Jesky; Punit Yadav; Rajbir Athwal; Mary Dutton; Charles J. Ferro; Paul Cockwell
Background Arterial stiffness is increased in patients with CKD and is a powerful predictor of cardiovascular morbidity and mortality. Use of the xanthine oxidase inhibitor allopurinol has been shown to improve endothelial function, reduce left ventricular hypertrophy and possibly improve cardiovascular outcome. We explored the relationship between use of allopurinol and arterial stiffness in patients with chronic kidney disease (CKD). Methods Cross-sectional observational study of 422 patients with CKD with evidence of, or at high risk of, renal disease progression. Arterial stiffness was determined by carotid-femoral pulse wave velocity (PWV). Results The mean age was 63±16 years, median estimated glomerular filtration rate was 25 (interquartile range: 19–31) ml/min/1.73 m2 and mean PWV was 10.2±2.4 m/s. Seventy-seven patients (18%) were receiving regular allopurinol, 61% at a dose of 100 mg/day (range: 50–400 mg/day). Patients receiving allopurinol had significantly lower peripheral pulse pressure, central pulse pressure, central systolic blood pressure, serum uric acid level tissue advanced glycation end product levels but comparable high-sensitivity C-reactive protein levels. Use of allopurinol was associated with lower PWV. After adjusting for age, gender, ethnicity, tissue advanced glycation end product level, peripheral pulse pressure, smoking pack years, presence of diabetes mellitus and use of angiotensin converting enzyme inhibitor or angiotensin II receptor blocker, the use of allopurinol remained a significant independent determinant of PWV (mean difference: −0.63 m/s; 95% CI, −0.09 to −1.17 m/s, p = 0.02). Conclusion In patients with CKD, use of allopurinol is independently associated with lower arterial stiffness. This study provides further justification for a large definitive randomised controlled trial examining the therapeutic potential of allopurinol to reduce cardiovascular risk in people with CKD.
Kidney International | 2015
Punit Yadav; Nelson Leung; Paul W. Sanders; Paul Cockwell
Kidney involvement is common in paraprotein-related diseases. A diversity of clinical presentations and histopathological features can occur secondary to tissue injury caused by precipitation or deposition of a clonal immunoglobulin, usually an immunoglobulin light chain. The paraprotein is either produced by multiple myeloma or by a clone of B-cell lineage that does not fulfill diagnostic criteria for multiple myeloma. The recent introduction of serum immunoglobulin free light chain assays, which accurately quantify both light chain isotypes to produce a ratio that indicates the presence or absence of a light chain paraprotein, is a major clinical development. However, as the interpretation of the assay can be challenging, the aim of this review is to clarify the role of serum and urinary light chain assays in the screening and diagnosis of paraprotein-related kidney disease.
Kidney diseases (Basel, Switzerland) | 2016
Punit Yadav; Mark Cook; Paul Cockwell
Background: Renal impairment (RI) is a common complication of multiple myeloma (MM). Around 50% of patients with MM have RI at presentation, and up to 5% require dialysis treatment. Severe acute kidney injury (AKI) as a cause of RI is a particular challenge as historically the survival of patients who sustain this complication and require dialysis is very poor. However, in this current period, survival is improving and the focus is on optimum use of novel chemotherapies and the evaluation of extra-corporeal therapies for removal of serum immunoglobulin light chains. Summary: RI in patients with MM is commonly associated with excess monoclonal free light chain (FLC) production; myeloma cast nephropathy is the predominant renal pathology in patients presenting with severe RI secondary to AKI. The majority of patients have mild to moderate RI and recover renal function. However, patients with more severe RI, in particular those with a requirement for dialysis, are less likely to recover renal function. Rapid diagnosis and prompt institution of anti-myeloma therapy is an important determinant of renal function recovery, through targeting early and sustained reduction of involved monoclonal FLC. Novel agents are associated with excellent disease response, and bortezomib is now widely used as a first-line agent in the management of MM in patients with severe RI. Extended haemodialysis using high cut-off dialysers is more effective for extracorporeal removal of FLC than plasma exchange, and clinical trials are in process. High-dose chemotherapy with autologous stem cell transplantation does have a role in patients with severe RI but requires careful patient selection. Key Messages: RI is very common in patients with MM, and renal function recovery is associated with improved clinical outcomes. We summarise the epidemiology of MM in the UK, present the impact of RI and renal function recovery on patient outcome, and describe the current management of MM in western countries. Facts from East and West: (1) A serum creatinine level >2 mg/dl has been reported in 16, 21, 24, and 33% of patients with MM in cohort studies from Japan, Europe, China, and Korea, respectively. A creatinine clearance rate <30 ml/min was observed in 30 and 15% of patients in Chinese and Western MM cohorts, respectively. The commonest cause of severe RI in patients with MM is myeloma cast nephropathy. (2) The efficacy of novel treatments (bortezomib, carfilzomib, thalidomide, and lenalidomide) has predominantly been assessed in Western patients. Bortezomib and dexamethasone are the current standard of care for MM and severe RI in the West. Severe RI is not a contraindication to autologous stem cell transplantation (ASCT). Most of the data are from the West; there are case reports from China describing good outcomes with ASCT. The removal of FLC by high-cut-off hemodialysis is under evaluation in randomized controlled trials (RCTs) in the West. Studies in this area are not yet conducted in China. In China, new treatments, such as bortezomib, are more widely used than before, and favorable results are being reported; however, RCT studies are still needed in this area to confirm the efficacy and safety of this and other novel treatments.
European Journal of Haematology | 2016
Punit Yadav; Colin A. Hutchison; Kolitha Basnayake; Stephanie Stringer; Mark Jesky; Lesley Fifer; Kym Ie Snell; J. Pinney; Mark T. Drayson; Mark Cook; Paul Cockwell
The aim of this study was to report the long‐term outcomes in patients with multiple myeloma (MM) who receive dialysis treatment for acute kidney injury (AKI) due to myeloma cast nephropathy and subsequently recover renal function.
PLOS ONE | 2016
Mark Jesky; Mary Dutton; Indranil Dasgupta; Punit Yadav; Khai Ping Ng; Anthony Fenton; Derek Kyte; Charles J. Ferro; Melanie Calvert; Paul Cockwell; Stephanie Stringer
Background Chronic kidney disease (CKD) is associated with reduced health-related quality of life (HRQL). However, the relationship between pre-dialysis CKD, HRQL and clinical outcomes, including mortality and progression to end-stage renal disease (ESRD) is unclear. Methods All 745 participants recruited into the Renal Impairment In Secondary Care study to end March 2014 were included. Demographic, clinical and laboratory data were collected at baseline including an assessment of HRQL using the Euroqol EQ-5D-3L. Health states were converted into an EQ-5Dindex score using a set of weighted preferences specific to the UK population. Multivariable Cox proportional hazards regression and competing risk analyses were undertaken to evaluate the association of HRQL with progression to ESRD or all-cause mortality. Regression analyses were then performed to identify variables associated with the significant HRQL components. Results Median eGFR was 25.8 ml/min/1.73 m2 (IQR 19.6–33.7ml/min) and median ACR was 33 mg/mmol (IQR 6.6–130.3 mg/mmol). Five hundred and fifty five participants (75.7%) reported problems with one or more EQ-5D domains. When adjusted for age, gender, comorbidity, eGFR and ACR, both reported problems with self-care [hazard ratio 2.542, 95% confidence interval 1.222–5.286, p = 0.013] and reduced EQ-5Dindex score [hazard ratio 0.283, 95% confidence interval 0.099–0.810, p = 0.019] were significantly associated with an increase in all-cause mortality. Similar findings were observed for competing risk analyses. Reduced HRQL was not a risk factor for progression to ESRD in multivariable analyses. Conclusions Impaired HRQL is common in the pre-dialysis CKD population. Reduced HRQL, as demonstrated by problems with self-care or a lower EQ-5Dindex score, is associated with a higher risk for death but not ESRD. Multiple factors influence these aspects of HRQL but renal function, as measured by eGFR and ACR, are not among them.
British Journal of Haematology | 2018
Felicity Evison; Jason Sangha; Punit Yadav; Y.S. Aung; Adnan Sharif; Jennifer A. Pinney; Mark T. Drayson; Mark Cook; Paul Cockwell
Adeyoju, A.B., Olujohungbe, A.B., Morris, J., Yardumian, A., Bareford, D., Akenova, A., Akinyanju, O., Cinkotai, K. & O’Reilly, P.H. (2002) Priapism in sickle cell disease; incidence, risk factors and complicationsan international multicentre study. BJU International, 90, 898–902. Ballas, K.S. & Lyon, D. (2015) Safety and efficacy of blood exchange transfusion for priapism complicating sickle cell disease. Journal of Clinical Apheresis., 31, 5–10. Broderick, G.A. (2012) Priapism and sickle cell anaemia: diagnosis and non-surgical therapy. The Journal of Sexual Medicine, 9, 88–103. Karsenty, G., Werth, E., Knapp, P.A., Curt, A., Schurch, A. & Bassetti, C. (2005) Sleep related painful erections. Nature clinical practice urology, 2, 256–260. Milkins, C., Berryman, J., Cantwell, C., Elliott, C., Haggas, R., Jones, J., Rowley, M., Williams, M. & Win, N.; for the. British Committee for Standards in Haematology (2013) Guidelines for pre-transfusion compatibility procedures in blood transfusion laboratories. British Committee for Standards in Haematology. Transfusion Medicine (Oxford, England) 23, 3–35. National Institute for Health and Care Excellence (NICE). (2016) Spectra Optia for automatic red blood cell exchange in patients with sickle cell disease. NICE medical technology guidance (MTG28). March 2016. Available at: www.nice.org.uk/guidance/mtg28/chapter/1-Recommendations (accessed 16 February 2016) Nolan, V.G., Wyszynski, D.F., Farrer, L.A. & Steinberg, M.H. (2005) Haemolysis associated priapism in sickle cell disease. Blood, 106, 3264–3267. Tsitsikas, D.A., Seligman, H., Sirigireddy, B., Odeh, L., Nzouakou, R. & Amor, R.J. (2014) Regular automated red cell exchange transfusion in the management of pulmonary hypertension in sickle cell disease. British Journal of Haematology., 167, 697–726. Tsitsikas, D.A., Sirigireddy, B., Nzouakou, R., Calvey, A., Quinn, J., Collins, J., Lewis, N., Orebayo, F., Todd, S. & Amos, R.J. (2016) Safety, tolerability and outcomes of regular automated red cell exchange transfusion for the management of chronic complications in sickle cell disease. Journal of Clinical Apheresis. doi 10.1002/jca.21447
British Journal of Haematology | 2017
Graham McIlroy; Jemma Mytton; Felicity Evison; Punit Yadav; Mark T. Drayson; Mark Cook; Guy Pratt; Paul Cockwell; J. Pinney
Pathological fractures are a common complication of plasma cell dyscrasias (PCD) and are associated with significant morbidity. Routine use of bisphosphonates over the past decade has aimed to reduce the risk of fractures in patients with multiple myeloma, but despite this, fractures continue to represent a significant burden of disease. In this study we report the fracture rate of hospital in‐patients with PCD in England. Data from the national registry Hospital Episode Statistics between 2001 and 2015 were used to determine fracture rate and its effect on overall survival. Fracture rates were 17·8 times higher than the general population in the first year after admission with PCD, and remained elevated for up to 10 years after first admission. The increased fracture risk preceded the first admission with PCD and, conversely, the incidence of PCD increased after admission with one or more fractures. Overall survival is improving with PCD, however poorer survival is found in patients with a preceding fracture (Hazard ratio 1·20). Despite widespread bisphosphonate use, fractures remain common in PCD, and are associated with poorer outcomes.
European Journal of Clinical Investigation | 2016
Mark Jesky; Stephanie Stringer; Anthony Fenton; Khai Ping Ng; Punit Yadav; Miguel Ndumbo; Katerina McCann; Tim Plant; Indranil Dasgupta; Stephen Harding; Mark T. Drayson; Frank A. Redegeld; Charles J. Ferro; Paul Cockwell
Mast cell activation can lead to nonclassical activation of the Renin–Angiotensin–Aldosterone System. However, the relevance of this to human chronic kidney disease is unknown. We assessed the association between serum tryptase, a product of mast cell activation, and progression to end‐stage renal disease or mortality in patients with advanced chronic kidney disease. We stratified patients by use of angiotensin‐converting enzyme inhibitors/angiotensin receptor II blockers (ACEi/ARB).
PLOS ONE | 2018
Anthony Fenton; Mark Jesky; Rachel E. Webster; Stephanie Stringer; Punit Yadav; Iain L. C. Chapple; Indranil Dasgupta; Stephen Harding; Charles J. Ferro; Paul Cockwell
Background Patients with chronic kidney disease (CKD) are at an increased risk of developing end-stage renal disease (ESRD). We assessed for the first time whether urinary free light chains (FLC) are independently associated with risk of ESRD in patients with CKD, and whether they offer incremental value in risk stratification. Materials and methods We measured urinary FLCs in 556 patients with CKD from a prospective cohort study. The association between urinary kappa/creatinine (KCR) and lambda/creatinine (LCR) ratios and development of ESRD was assessed by competing-risks regression (to account for the competing risk of death). The change in C-statistic and integrated discrimination improvement were used to assess the incremental value of adding KCR or LCR to the Kidney Failure Risk Equation (KFRE). Results 136 participants developed ESRD during a median follow-up time of 51 months. Significant associations between KCR and LCR and risk of ESRD became non-significant after adjustment for estimated glomerular filtration rate (eGFR) and albumin/creatinine ratio (ACR), although having a KCR or LCR >75th centile remained independently associated with risk of ESRD. Neither KCR nor LCR as continuous or categorical variables provided incremental value when added to the KFRE for estimating risk of ESRD at two years. Conclusions Urinary FLCs have an association with progression to ESRD in patients with CKD which appears to be explained to a degree by their correlation with eGFR and ACR. Levels above the 75th centile do have an independent association with ESRD, but do not improve upon a current model for risk stratification.
BMC Nephrology | 2017
Jennifer L.J. Heaney; John P. Campbell; Punit Yadav; Ann E. Griffin; Meena Shemar; J. Pinney; Mark T. Drayson